학술논문

Impact of Brazil's Bolsa Família Programme on cardiovascular and all-cause mortality: a natural experiment study using the 100 Million Brazilian Cohort.
Document Type
Article
Source
International Journal of Epidemiology. Dec2022, Vol. 51 Issue 6, p1847-1861. 15p.
Subject
*MORTALITY
*CONDITIONAL cash transfer programs
*STATISTICAL models
*EARLY death
*POOR people
Language
ISSN
0300-5771
Abstract
Background Cardiovascular disease (CVD) has a disproportionate effect on mortality among the poorest people. We assessed the impact on CVD and all-cause mortality of the world's largest conditional cash transfer, Brazil's Bolsa Família Programme (BFP). Methods We linked administrative data from the 100 Million Brazilian Cohort with BFP receipt and national mortality data. We followed individuals who applied for BFP between 1 January 2011 and 31 December 2015, until 31 December 2015. We used marginal structural models to estimate the effect of BFP on all-age and premature (30–69 years) CVD and all-cause mortality. We conducted stratified analyses by levels of material deprivation and access to healthcare. We checked the robustness of our findings by restricting the analysis to municipalities with better mortality data and by using alternative statistical methods. Results We studied 17 981 582 individuals, of whom 4 855 324 were aged 30–69 years. Three-quarters (76.2%) received BFP, with a mean follow-up post-award of 2.6 years. We detected 106 807 deaths by all causes, of which 60 893 were premature; and 23 389 CVD deaths, of which 15 292 were premature. BFP was associated with reductions in premature all-cause mortality [hazard ratio (HR) = 0.96, 95% CI = 0.94–0.98], premature CVD (HR = 0.96, 95% CI = 0.92–1.00) and all-age CVD (HR = 0.96, 95% CI = 0.93–1.00) but not all-age all-cause mortality (HR = 1.00, 95% CI = 0.98–1.02). In stratified and robustness analyses, BFP was consistently associated with mortality reductions for individuals living in the two most deprived quintiles. Conclusions BFP appears to have a small to null effect on premature CVD and all-cause mortality in the short term; the long-term impact remains unknown. [ABSTRACT FROM AUTHOR]